F. Hoffmann-La Roche AG


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2018 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 August 2018 - 31 July 2019

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 August 2018 - 31 July 2019 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

141 49.95

Outputs by subject (FC)

Subject AC FC
Life Sciences 120 40.37
4 1.40
4 1.49
4 1.96
1 0
1 0.07
3 0.21
3 1.67
8 3.70
2 0.14
7 1.56
4 2.93
2 1.04
7 2.05
2 0.21
17 3.42
2 0.03
5 0.73
6 1.72
1 0.21
1 0.03
2 0.90
1 0.05
3 1.16
11 4.74
1 0.57
1 0
9 4.66
1 0.11
7 3.62
Chemistry 24 10.09
Physical Sciences 6 0.97

Highlight of the month

Some myelin-making cells missing in multiple sclerosis



The brains of people with multiple sclerosis have different kinds of oligodendrocyte cells than people without the disease, even in brain regions not thought affected by the chronic inflammatory disorder.

The study — one of the first to use single-cell RNA sequencing to interrogate a neurological disease — could help explain how multiple sclerosis progresses and how to improve treatment strategies.

Oligodendrocytes help wrap nerve fibres in the protective myelin sheath that is lost in multiple sclerosis.

Starting with single oligodendrocytes from the white matter of healthy brains, a research team that included scientists from Roche identified many subpopulations of these myelin-making cells. In brains from multiple sclerosis-affected patients, however, certain subpopulations were missing or altered, both within disease lesions and in normal-appearing tissue.

The findings could help explain why the restoration of damaged myelin is impaired in multiple sclerosis.

Supported content

  1. Nature 566, 543–547 (2019). doi: 10.1038/s41586-019-0903-2

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 August 2018 - 31 July 2019

International vs. domestic collaboration by FC

  • 8.09% Domestic
  • 91.91% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (FC), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs